BOSTON–Within3, a healthcare technology company providing data analytics and market intelligence to the pharmaceutical industry, has appointed Ira Daly as Chief Operating Officer, bringing in a veteran IQVIA executive with more than 18 years of experience in biopharmaceutical business development.
Daly will oversee Within3’s business development, client success, and strategic partnerships as the company seeks to expand its relationships with pharmaceutical and biotechnology companies.
Before joining Within3, Daly spent more than 18 years at IQVIA, where he built and managed business development teams serving pharmaceutical, biotechnology, and medical technology companies across multiple therapeutic areas.
Most recently, he served as Senior Vice President of Offering Development at IQVIA, where he assembled a team of data and analytics specialists and worked on developing artificial intelligence agents to improve the delivery and implementation of customer solutions.
Previously, Daly was Senior Vice President of Biotech and Midsize Business Development for the United States and Canada. In that position, he led business development operations and established partnerships with biotechnology companies, academic institutions, venture capital firms, and patient organizations.
Throughout his career, he has contributed to commercial and development initiatives supporting the approval of numerous treatments.
“Ira understands that the most valuable partnerships in our industry are built over years, not contracts, and that is exactly what Within3 needs as we enter our next phase of growth,” said Erin Mistry, Chief Executive Officer of Within3. “Our clients increasingly want a trusted partner embedded with their business and technology teams, one that understands the clinical and commercial questions shaping their future, not just their day-to-day. Ira will help us become that partner for every client we serve.”
Within3 operates a technology platform that combines public and private data with expert networks to help pharmaceutical companies assess market conditions, understand clinical practices, and make decisions throughout the drug development and commercialization process.
The company says its platform is used by all 20 of the world’s largest pharmaceutical companies.
Aly Madjerich, Senior Vice President of Global Marketing at Within3, also welcomed the appointment.
“I’m thrilled to have Ira’s depth of industry experience on the team – and a partner who shares our commitment to relationships built on honest conversations and a willingness to tackle tough problems, together. Those relationships are essential to building solutions that better serve the industry and the patients who depend on it.”
As Chief Operating Officer, Daly will focus on expanding Within3’s commercial operations, strengthening customer relationships, and developing partnerships with emerging biotechnology companies and established global pharmaceutical manufacturers.
His responsibilities will also include coordinating the company’s commercial and client service teams to support pharmaceutical customers across different stages of product development and commercialization.
“Throughout my career, I’ve seen how the right partner can influence the success of a development program, if and how physicians prescribe the treatment, and ultimately its commercial success,” said Daly. “Within3 offers biopharma teams something they’ve never had: a connected, real-time view of the market, so they can act when it matters most. I’m excited to help more clients put that intelligence to work and to build partnerships that deliver measurable results.”
Daly holds a Master of Science in Cell and Molecular Biology from Fordham University and a Bachelor of Science in Chemistry from Saint Joseph’s University. (Source: IANS)
